MOTS-c dosing protocol
MOTS-c dosing — conservative, standard, and aggressive patterns from the strength community, body-weight scaling, injection logistics, and cycle length.
Updated May 7, 2026 · 4 min read
The MOTS-c protocol playbook is still being written. The peptide was only identified in 2015, there are no FDA-approved indications, and human dosing is derived from animal studies and a relatively short period of community self-experimentation. The doses below reflect what's most commonly reported by users running MOTS-c for metabolic and exercise-capacity goals — not clinical guidance.
Quick reference
| Detail | Value |
|---|---|
| Class | Mitochondrial-derived peptide, AMPK activator |
| Route | Subcutaneous injection |
| Cadence | Once weekly to 3x weekly |
| Typical weekly dose | 5–10 mg |
| Cycle length | 8–12 weeks |
| Common vials | 5 mg or 10 mg |
Note the units: MOTS-c is dosed in milligrams per week, not micrograms. This is a different scale from BPC-157, sermorelin, or most other peptides in the strength category.
The three reported patterns
| Pattern | Weekly dose | Cadence | Best fit |
|---|---|---|---|
| Conservative | 5 mg | 2.5 mg twice weekly (Mon/Thu) | First cycle, smaller users, dialing in tolerance |
| Standard | 10 mg | 3.3–5 mg, 2–3x weekly | Most reported pattern, balances steady-state with fewer injections |
| Aggressive | 10 mg | 10 mg single weekly bolus | Convenient, more pronounced post-injection effects, harder on tolerability |
The standard pattern is what most experienced users settle on after a first cycle. Splitting 10 mg across two or three weekly injections smooths the post-injection metabolic shift and tends to be better tolerated than a single weekly bolus.
Body-weight scaling
| Body weight | Weekly dose |
|---|---|
| Under 165 lb (75 kg) | 5–7.5 mg |
| 165–220 lb (75–100 kg) | 7.5–10 mg |
| Over 220 lb (100 kg+) | 10 mg |
Scaling above 10 mg/week doesn't reliably scale benefits. AMPK activation has a ceiling, and side-effect intensity (mild GI, lethargy, hypoglycemia at the bottom edge) tends to rise faster than the metabolic signal above this dose.
Reconstitution math
MOTS-c commonly ships in 5 mg or 10 mg vials. Two practical mixes:
5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL.
A 2.5 mg dose → 1 mL → 100 units on a U-100 insulin syringe.
10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.
A 5 mg dose → 1 mL → 100 units on a U-100 insulin syringe.
For aggressive single-weekly 10 mg doses, you'll need either a more concentrated mix or a larger syringe, since 100 units on a U-100 caps the single-injection volume. The reconstitution calculator handles the arithmetic.
Injection site and timing
SubQ into the abdomen, flank, or thigh. Rotate sites to avoid local reactions. Most reported users inject in the morning, but timing isn't a strong variable for MOTS-c the way it is for sermorelin or ipamorelin — the AMPK-activation effect plays out over hours and days, not in a tight post-injection window.
The empty-stomach question that matters for GH secretagogues is less critical here. Some users prefer fasted injection on the theory that AMPK activation is most relevant in a fasted, energy-deficit state. There's no rigorous human data either way; pick a consistent time and stick to it.
Cycle length
The most-reported cycle is 8–12 weeks on, 4–8 weeks off. Reasoning:
- Metabolic effects (insulin sensitivity, glucose handling) take 4–6 weeks to express
- Endurance and exercise-capacity changes need at least 8 weeks to show consistently
- Continuous use isn't well-studied — receptor adaptation is theoretical here, not documented
- A 4–8 week off period gives the body a normal-physiology window before the next cycle
For more on cycle structure, see MOTS-c cycling patterns.
What to expect on cycle
The signal builds gradually:
- Weeks 1–2: subjective injection-site reactions, occasional mild GI in first 1–2 doses, sometimes a brief energy dip in the first week
- Weeks 3–6: improved glucose handling reported (smoother post-meal energy, reduced afternoon crashes), modest body-composition shifts in users running a calorie deficit
- Weeks 7–12: endurance improvements at the end of cycle if you're training, consolidated metabolic effects
MOTS-c is not a "feel" drug like a peptide stimulant. It doesn't produce a noticeable post-injection rush. The signal is in your bloodwork (fasting glucose, insulin, HbA1c trend), your training response, and how you handle a meal at week 8 vs week 1.
Common mistakes
- Dosing in micrograms. MOTS-c is mg-scale. A 200 mcg dose is essentially nothing.
- Quitting at week 4. Metabolic effects need 6+ weeks to clearly express.
- Stacking with metformin without medical guidance. Both activate AMPK; the additive effect on glucose isn't well-characterized.
- Expecting GLP-1-style fat loss. MOTS-c is not appetite-suppressing. Different mechanism, different effect profile.
- Skipping bloodwork. A fasting glucose and insulin panel before cycle start is the cheapest way to know whether MOTS-c is doing anything for you.